JPRN-UMIN000028178已完成未知
Effects of Evolocumab on carotid plaque. - Effects of Evolocumab on carotid plaque.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of coronary artery disease or valvular disease or heart failure of NYHA class 3 or higher 2) Arrhythmia with poor control within 3 months 3) High blood pressure with poor control(systolic blood pressure at rest > 180 mmHg) 4) Type 1 diabetes or poorly controlled diabetes (HbA1c > 9.0 %) 5) Creatine kinase is at least 3 times higher than normal upper limit. 6) History of PCSK9 inhibitor administration in the past. 7) History of administration of cyclosporine and steroid for more than 2 weeks within 3 months before entry of the study. 8) History of malignant tumor. 9) Active infectious diseases, renal failure, blood diseases, gastrointestinal diseases and metabolic diseases oher than diabetes / dyslipidemia 10) Pregnancy 11) Inability to evaluate by carotid ultrasonography by calcification. 12) Other conditions which the physician deems inappropriate.
研究者
相似试验
进行中（未招募）
1 期
Effect of Evolocumab in people at risk of strokesCarotid stenosisEUCTR2018-001234-18-GBImperial College NHS Trust70
进行中（未招募）
4 期
Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)Carotid Artery StenosisNCT03931161Imperial College Healthcare NHS Trust33
Unknown
4 期
CARotid plaqUe StabilizatiOn and Regression With Evolocumab.Carotid Artery DiseaseNCT04730973Azienda Ospedaliera Ordine Mauriziano di Torino130
招募中
不适用
Efficacy of Evolocumab in patients with arteriosclerosis obliterans.arteriosclerosis obliteransJPRN-UMIN000032844Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui20
已完成
不适用
Impact of lipid-lowering therapy with Evolocumab on coronary plaque regression in patients with coronary artery diseaseJPRN-UMIN000023448Chiba University Graduate School of Medicine3